News
ABBV
167.81
+0.01%
0.01
AbbVie reports positive results from Rinvoq versus Dupixent study
AbbVie reports positive results from Rinvoq versus Dupixent study. Sanofi and Regeneron's Dupixen also in the study. Abbvie says its drug is more effective in treating symptoms of moderate-to-severe atopic dermatitis.
Seeking Alpha · 7h ago
Notable earnings before Friday's open
Seeking Alpha · 8h ago
Notable ETF Outflow Detected - ACWI, PG, ABBV, BAC
NASDAQ · 8h ago
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1
Seeking Alpha · 8h ago
AbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Study
NASDAQ · 8h ago
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie's drug, Rinvoq, found to be more effective than Regeneron's Dupixent in study. Atopic dermatitis is a type of inflammatory skin condition. Abbvie says drug helped 19.9% of patients achieve complete skin clearance after 16 weeks.
Reuters · 10h ago
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
NASDAQ · 10h ago
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study. The drug, for treating a type of inflammatory skin condition, showed superior efficacy to Sanofi and Regeneron in a late-stage head-to-head study. Abbvie's drug, Rinvoqu, is being tested to treat a skin condition.
Reuters · 10h ago
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys. Global stock indices continued an upward trend in March, with both U.S. Stocks rising by 3%. Nvidia unveiled its groundbreaking Blackwell chip at GTC 2024. The S&P 500 recorded its longest positive monthly streak since 2021.
Seeking Alpha · 11h ago
AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance and no to little itch. AbbVie's study was a Phase 3b/4 head-to-head study. The safety profile of upadacinib was consistent with previous atopic dermatitis studies.
Benzinga · 11h ago
ABBVIE INC: SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PROFILE IN PREVIOUS ATOPIC DERMATITIS STUDIES
Reuters · 11h ago
ABBVIE INC - THERE WAS ONE SERIOUS INFECTION REPORTED IN DUPILUMAB GROUP AND NONE IN UPADACITINIB GROUP
Reuters · 11h ago
Polaris Global Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter. The Polaris Global Equity Composite returned 6.19% (net of fees), lagging the benchmark. Global portfolio had absolute positive gains across all sectors, led by financials, industrials and consumer discretionary holdings.
Seeking Alpha · 11h ago
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance and no to little itch. AbbVie's study was a Phase 3b/4 head-to-head study. The safety profile of upadacinib was consistent with previous atopic dermatitis studies.
PR Newswire · 11h ago
UPDATE 4-Lazard profit beats estimates as dealmaking rebound fuels record revenue
Lazard's first-quarter profit beats estimates as dealmaking rebound fuels record revenue. Firmwide and advisory revenues surged to record levels. The bank advised on a string of high-profile deals in the first quarter. Lazard's adjusted revenue jumped 42% to $747 million.
Reuters · 12h ago
UPDATE 3-Lazard posts better-than-expected profit on deals, assets boost
Lazard posts better-than-expected profit on deals, assets boost in first quarter. Investment bank's adjusted revenue jumped 42% to $747 million. Firm advised on a string of high-profile mergers and acquisitions in the quarter. Lazard's assets under management rose to $250 billion from $232 billion.
Reuters · 12h ago
UPDATE 2-Lazard posts first-quarter profit on deals, assets boost
Lazard posts first-quarter profit on deals, assets boost. Investment bank's profit boosted by a string of high-profile mergers and acquisitions it advised on in the first quarter. Lazard's assets under management rose to $250 billion in the quarter from $232 billion a year earlier.
Reuters · 12h ago
Scholz promises support for pharma sector in Germany as Merck invests
German Chancellor Olaf Scholz promises support for pharma sector in Germany as Merck invests. Merck is investing 1.5 billion euros in Germany. The drugmaker plans to use its life sciences Advanced Research Centre in Darmstadt. Germany has sought to improve conditions for the pharma and biotech sector.
Reuters · 13h ago
Will Higher Keytruda Sales Drive Merck's Q1
NASDAQ · 21h ago
Abbvie breaks six day winning cycle, trades in the red
Abbvie breaks six day winning cycle, trades in the red on Wednesday. The stock closed down 1.03% at $167.80. The company has outperformed the broader S&P 500 market, which has gained 6.30%. AbbVie will report Q1 results this week.
Seeking Alpha · 1d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.